31 biotechnology, biopharma and life science companies and educational institutions at the forefront of mRNA and next-generation encoding RNA therapeutics and vaccine development have launched the Alliance for mRNA Medicines (AMM).

AMM is the first and only scientific and policy organisation singularly focused on advancing and advocating for global mRNA innovation and the sector's top policy priorities before legislative and regulatory bodies in North America, Europe and Asia.

Alliance members represent some of the most recognised mRNA innovators in the field. Bringing the best minds together, AMM aims to overcome the most critical obstacles inhibiting the advancement of mRNA research, development and manufacturing.

AMM's founding members include- Acuitas Therapeutics; Akron Biotech; Arcturus Therapeutics; Australian National University; BioNTech; CSL; Curapath; CureVac; Cytiva; Cytonus; Danaher; De Novo Biotherapeutics; Etherna; Ethris ; Exothera; Ginkgo Bioworks; Johns Hopkins University; Maravai LifeSciences; MaxCyte; Mayo Clinic; MJH Life Sciences; Nutcracker Therapeutics; Precision for Medicine; Providence Therapeutics; Quantoom Biosciences; Replicate; Sail Biomedicines; Texas A&M Engineering Experiment Station; Vernal Biosciences; Verve Therapeutics; Why We Vax;